Combining chemotherapy and targeted therapies in metastatic colorectal cancer
Palabras clave : 
Targeted therapy
Colorectal cancer
Fecha incorporación: 
Editorial : 
Baishideng Publishing Group
Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, Garcia-Foncillas J, et al. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007 Nov 28;13(44):5867-5876.
Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, cetuximab and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts have focused on identifying novel agents targeting specific growth factor receptors, critical signal transduction pathways or mediators of angiogenesis. In addition, several clinical trials have suggested that some of these molecularly targeted drugs can be safely and effectively used in combination with conventional chemotherapy. In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer.

Ficheros en este registro:
World J Gastroenterol 2007. 5867.pdf
340,9 kB
Adobe PDF

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.